Arch Therapeutics, Inc. announced that it has appointed Michael S. Abrams its Chief Financial Officer effective May 10, 2021. In alignment with the company’s succession plan, Mr. Abrams joins Arch’s financial team, one week before assuming the role currently held by the company’s Chief Financial Officer, Richard Davis. Mr. Davis will remain with the Company during a Transition Period, which will end on June 30, 2021, after which he will support the Company in a consulting role through December 31, 2021.